PineBridge Investments L.P. boosted its position in Natus Medical Inc. (NASDAQ:BABY) by 3.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,200 shares of the company’s stock after buying an additional 149 shares during the period. PineBridge Investments L.P.’s holdings in Natus Medical were worth $159,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Acrospire Investment Management LLC increased its position in shares of Natus Medical by 39.1% in the second quarter. Acrospire Investment Management LLC now owns 2,844 shares of the company’s stock worth $108,000 after buying an additional 800 shares during the last quarter. Invictus RG purchased a new position in shares of Natus Medical during the first quarter worth $148,000. Teacher Retirement System of Texas increased its position in shares of Natus Medical by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 4,602 shares of the company’s stock worth $174,000 after buying an additional 562 shares during the last quarter. Intrust Bank NA purchased a new position in shares of Natus Medical during the second quarter worth $207,000. Finally, Suntrust Banks Inc. increased its position in shares of Natus Medical by 3.7% in the second quarter. Suntrust Banks Inc. now owns 5,776 shares of the company’s stock worth $218,000 after buying an additional 204 shares during the last quarter. Institutional investors and hedge funds own 87.92% of the company’s stock.
Natus Medical Inc. (NASDAQ:BABY) opened at 39.29 on Friday. The firm has a market capitalization of $1.27 billion, a P/E ratio of 33.87 and a beta of 0.85. The firm has a 50 day moving average of $40.41 and a 200 day moving average of $36.82. Natus Medical Inc. has a 12-month low of $29.54 and a 12-month high of $51.05.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.36 by $0.03. The company earned $96 million during the quarter, compared to the consensus estimate of $92.71 million. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.34 EPS. On average, analysts forecast that Natus Medical Inc. will post $1.58 EPS for the current fiscal year.
A number of brokerages recently weighed in on BABY. Raymond James Financial Inc. upgraded shares of Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 target price on the stock in a report on Tuesday, September 13th. Zacks Investment Research downgraded shares of Natus Medical from a “buy” rating to a “hold” rating in a report on Wednesday.
In related news, insider James B. Hawkins acquired 10,000 shares of Natus Medical stock in a transaction dated Wednesday, September 28th. The stock was bought at an average price of $38.48 per share, with a total value of $384,800.00. Following the transaction, the insider now directly owns 459,725 shares in the company, valued at approximately $17,690,218. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.80% of the company’s stock.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc. (NASDAQ:BABY).
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.